MedDataX Logo

Utilization Patterns of Pulmicort in Real Life Practice

NCT ID: NCT00660569

Last Updated: 2010-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

asthma treatment utilization real life practice

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
* Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion Criteria

* Disability that, from investigator point of view, prevent from complying the follow up schedule
* To have participated in any clinical study in the past 6 months
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javier Nuevo Rivero

Role: STUDY_DIRECTOR

AstraZeneca MC SpainEpidemiologyValue Demonstration Unit

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Barcelona, Barcelona, Spain

Site Status

Research Site

Sabadell, Barcelona, Spain

Site Status

Research Site

Alcorcón, Madrid, Spain

Site Status

Research Site

Leganés, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

San Sebastián de los Reyes, Madrid, Spain

Site Status

Research Site

Murcia, Murcia, Spain

Site Status

Research Site

Olivares, Sevilla, Spain

Site Status

Research Site

Toledo, Toledo, Spain

Site Status

Research Site

Fuentes de Ebro, Zaragoza, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-RES-PUL-2007/1

Identifier Type: -

Identifier Source: org_study_id